Differentiation of Langerhans cells in Langerhans cell histiocytosis.
Langerhans cell histiocytosis (LCH) consists of lesions composed of cells with a dendritic Langerhans cell (LC) phenotype. The clinical course of LCH ranges from spontaneous resolution to a chronic and sometimes lethal disease. We studied 25 patients with various clinical forms of the disease. In bone and chronic lesions, LCH cells had immature phenotype and function. They coexpressed LC antigens CD1a and Langerin together with monocyte antigens CD68 and CD14. Class II antigens were intracellular and LCH cells almost never expressed CD83 or CD86 or dendritic cell (DC)-Lamp, despite their CD40 expression. Consistently, LCH cells sorted from bone lesions (eosinophilic granuloma) poorly stimulated allogeneic T-cell proliferation in vitro. Strikingly, however, in vitro treatment with CD40L induced the expression of membrane class II and CD86 and strongly increased LCH cell allostimulatory activity to a level similar to that of mature DCs. Numerous interleukin-10-positive (IL-10(+)), Langerin(-), and CD68(+) macrophages were found within bone and lymph node lesions. In patients with self-healing and/or isolated cutaneous disease, LCH cells had a more mature phenotype. LCH cells were frequently CD14(-) and CD86(+), and macrophages were rare or absent, as were IL-10-expressing cells. We conclude that LCH cells in the bone and/or chronic forms of the disease accumulate within the tissues in an immature state and that most probably result from extrinsic signals and may be induced to differentiate toward mature DCs after CD40 triggering. Drugs that enhance the in vivo maturation of these immature DCs, or that induce their death, may be of therapeutic benefit.
Institut Fédératif de Recherche Necker-Enfants Malades (Service d'Anatomie Pathologique EA 219, Unité Mixte de Recherche 8603 CNRS/Université Paris-V, Paris, France. geissman@necker.fr
F
F
Geissmann
Y
Y
Lepelletier
S
S
Fraitag
J
J
Valladeau
C
C
Bodemer
M
M
Debré
M
M
Leborgne
S
S
Saeland
N
N
Brousse
D015703:Antigens, CD / Q000096:biosynthesis / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D000954:Antigens, Surface / Q000096:biosynthesis; D051940:B7-2 Antigen; D019013:CD40 Antigens / Q000494:pharmacology; D002454:Cell Differentiation; D016922:Cellular Senescence / Q000187:drug effects / Q000502:physiology; D004803:Eosinophilic Granuloma / Q000473:pathology; D006646:Histiocytosis, Langerhans-Cell / Q000473:pathology*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D007801:Langerhans Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D037181:Lectins, C-Type; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008264:Macrophages / Q000378:metabolism; D037241:Mannose-Binding Lectins; D008562:Membrane Glycoproteins / Q000378:metabolism; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000954:Antigens, Surface; D051940:B7-2 Antigen; D019013:CD40 Antigens; D000949:Histocompatibility Antigens Class II; D016753:Interleukin-10; D037181:Lectins, C-Type; D018950:Lipopolysaccharide Receptors; D037241:Mannose-Binding Lectins; D008562:Membrane Glycoproteins; C121916:CD207 protein, human; C067980:CD68 antigen, human; D000097382:CD68 Molecule